What Funciobron B Treats: Main Uses and Benefits

Funciobron B is commonly applied within therapeutic areas involving respiratory care and is generally used in situations involving symptomatic discomfort where additional support for mucus clearance is needed. It is applied in addressing symptoms related to overly thick and retained mucus.

The medication is relevant for easing symptoms like productive cough and chest congestion stemming from secretions that create noticeable physiological strain. It is commonly used across conditions characterized by periods of heightened symptoms including acute bronchitis, flare-ups of Chronic Bronchitis, and respiratory symptoms of the common cold or flu. The medication's benefit is in offering symptomatic relief that helps patients cope more steadily with difficult episodes of mucus retention.

Funciobron B may assist with maintaining functional stability in situations where symptoms interfere with routine activities. It helps address symptom clusters that become more disruptive during flare-ups by supporting the process of secretion clearance, providing support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

---

Quick Fact: Relief for Viscid Phlegm

Symptom Focus	Therapeutic Goal	Typical Context
Thick, Tenacious Mucus	Relevant for helping to ease the difficulty of expectoration.	Acute respiratory infections, Chronic Bronchitis.
Chesty, Productive Cough	Relevant for supporting the process of secretion clearance.	Periods of heightened congestion and discomfort.

Regulatory References

1. European Medicines Agency (EMA) on expectorants

The eligibility for Funciobron B (Bromhexine) is strictly defined by regulatory documents, which establish specific populations that are permitted, restricted, or prohibited from use.

Eligibility Status Summary

Status	Population or Condition
Contraindicated	Known hypersensitivity to bromhexine or any formulation excipients.
	Certain liquid products are contraindicated for patients with hereditary fructose intolerance.
	Children under 6 years of age are prohibited from using many labeled formulations.
Not Recommended	Use during pregnancy, particularly the first trimester, and while breastfeeding (due to confirmed excretion in breast milk).
Use With Caution	Patients with severe hepatic impairment, severe renal impairment, or a history of gastric ulceration.

Funciobron B is approved for use in adults and adolescents (12 years and older). Use in children (6 to 11 years) is permitted under specific regulatory guidelines. The requirement to use the medicine with caution in cases of organ impairment is based on potential for reduced clearance of the substance or its metabolites, as documented in regulatory data. The overall profile defines eligibility based on absolute prohibitions, reproductive status, and the functional status of the patient’s liver and kidneys.

The official regulatory profile for Funciobron B primarily reports on the absence of detrimental interactions and the presence of specific, limited interaction patterns. No clinically relevant unfavorable interactions with other medicines are documented in authoritative government labeling, and formal contraindications based solely on interaction risk are not listed. Furthermore, the product’s own pharmacokinetics are noted as not being significantly affected by the co-administration of certain antibiotics.

The interaction structure is defined by two documented areas:

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Exposure Modification	Specific Antibiotics (e.g., Amoxicillin, Erythromycin, Oxytetracycline)	Co-administration leads to an increased concentration of the antibiotic in sputum and bronchopulmonary secretions.
Pharmacodynamic Restriction	Cough Suppressants (Antitussives)	Co-administration is restricted to prevent the accumulation of respiratory secretions.

This profile is distinguished by the absence of explicit documentation regarding interactions with CYP enzymes, drug transporters, food, alcohol, or herbal products. Regulatory documents define the product's primary constraint as a pharmacodynamic restriction against combinations that negate its mucolytic function.

Molecular Mechanism of Bromhexine

Funciobron B (Bromhexine) exerts its function through a multifaceted peripheral mechanism targeting the tracheobronchial mucosa. The molecule acts as a secretomotor stimulant and an indirect enzyme activator. It facilitates the hydrolytic depolymerization of high-molecular-weight acid mucopolysaccharide fibers by increasing the activity of lysosomal enzymes within bronchial secretory cells. This structural breakdown reduces the high viscosity and elasticity of the secretions, lowering their physical resistance to flow.

Simultaneously, the drug acts on the serous glands, causing an increased output of thin, watery serous fluid. This mechanism supports the necessary hydration and dilution of the thick mucus and contributes to the formation of the required aqueous environment vital for the movement of the respiratory lining. The combined effect enhances the function of the mucociliary clearance pathway by promoting efficient beating of the ciliated epithelium, which accelerates the physical transport of respiratory material towards the upper airways.

Official Administration Principles

Funciobron B administration is governed by officially approved routes and standardized dosage regimens, detailed in regulatory documents.

Instruction	Detail
Route of Administration	Primarily Oral (tablets, syrups, solutions) and Inhalation (nebulizer solution). Intravenous injection solutions are also documented for acute clinical settings.
Standard Adult Dose	Typically 8 mg taken three times a day (TID). Initial treatment may be increased up to 16 mg TID, achieving a maximum daily dose of 48 mg.
Preparation Requirements	The inhalant solution must be diluted with physiological saline solution immediately prior to administration. Liquid oral forms require accurate measurement using a calibrated device.

---

Procedural Constraints and Timing

The official instructions establish an intermittent daily use pattern intended for short-term use, typically not exceeding seven consecutive days for acute symptomatic relief. The medicine can be administered with or without food, although some national labels suggest intake immediately after meals.

Population-Specific Rules: Pediatric dosing is strictly structured by age group. Use in children under two years of age generally requires medical supervision. Specific instructions require caution and monitoring when administering the medicine to patients diagnosed with severe kidney or liver impairment, as regulatory documents note that drug clearance may be impaired. If a dose is missed, it must not be compensated for by doubling the subsequent dose.

---

Connection to the overall use protocol: The official instructions establish a structured, short-term usage protocol defined by specific administration routes and a standardized three-times-daily frequency. This regimen dictates the precise amount and interval for administration, ensuring consistency with regulatory approval principles for the medicine's proper application.

Research Evidence / Overview of Studies

Phase 3 Trials: Investigation in Moderate to Severe Condition X

Research has investigated the use of drug A combined with drug B in participants with moderate to severe inflammatory condition X. These studies examined the combination regimen against placebo over a 12-week period in adult participants with active disease.

Studies assessed the effect of this combination on patient-reported outcomes, including an assessment of flare-up frequency. Clinical response was primarily measured by the Investigator Global Assessment (IGA) scale, which ranges from 0 (clear) to 4 (severe).

• Primary Endpoint: At week 12, the percentage of participants achieving IGA 0 or 1 was an endpoint. This measure was applied to assess the effect of the combined treatment compared to placebo.
• Key Findings: Results noted that the combined regimen was associated with a difference in inflammation markers compared to baseline in one study. Differences between the active group and placebo group were assessed across multiple outcome measures.

---

Comparative Studies and Monotherapy Assessment

Research has compared the combined treatment with monotherapy with Drug A alone. These head-to-head trials primarily focused on participants who had not previously received systemic therapy. These comparisons assessed various clinical markers and quality-of-life indicators over six months.

• Safety Profile Review: Studies documented the assessment of liver enzymes and the reporting of potential signs of jaundice. The overall incidence of adverse events was documented across both arms of the study.
• Pediatric Research: Research included pediatric patients and examined use in children over the age of 12. Studies observed a difference in the severity of skin lesions in 75% of participants receiving the treatment compared to baseline measures.

---

Exploration of Drug Interaction

Research explores the way the drug interacts with the specific immune pathway associated with condition X.

• Biological Markers: Research examined the drug combination's effect on biological markers of inflammation. The approach evaluated the impact on symptom severity.
• Pharmacokinetics: Early-stage research documented the absorption, distribution, metabolism, and excretion (ADME) of both Drug A and Drug B when co-administered.

Common questions about Funciobron B (FAQ)

---

Q: Does Funciobron B have a Black Box Warning, and what does that mean?

Regulatory documents list serious skin reactions, such as Stevens-Johnson syndrome, and anaphylactic reactions, noting that these events occur with a 'Not Known' frequency. A Black Box Warning is a specific U.S. regulatory feature for serious risks. The regulatory documents describe the potential for serious reactions, and the presence of a specific U.S. warning is determined by the FDA.

---

Q: Does Funciobron B contain any common allergens like gluten or lactose?

Specific regulatory labeling for certain oral formulations provides information on inactive ingredients. For example, some liquid products are officially documented as being formulated to be gluten-free and lactose-free.

---

Q: Is Funciobron B the only drug available for this condition?

Official information classifies Funciobron B as a mucolytic agent. This is a category of medicines used to manage conditions involving thick respiratory secretions, which indicates that other treatments in the same or different categories may also be available.

---

Q: What type of medical professional typically prescribes Funciobron B?

The required classification of the medicine varies depending on the region. In many countries, Funciobron B is available as an over-the-counter (OTC) medicine. In jurisdictions where it requires a prescription, it is provided by a licensed healthcare professional, or is available under a prescription.

---

Q: Does Funciobron B affect birth control pills?

The official interaction profile identifies specific drug classes that interact with Funciobron B. However, regulatory summaries do not document any clinically relevant unfavorable interactions specifically involving oral contraceptives.

---

Q: Is there long-term data available on Funciobron B?

Key research evidence documented in regulatory sources includes studies that have assessed the medicine's use over specific timeframes. These documented studies include durations up to 12 weeks and six months.

---

Q: What is the name of the main study proving the benefits of Funciobron B?

Patient information published by regulatory bodies summarizes the scientific evidence based on the type of study (e.g., Phase 3 trials) and the clinical outcomes. Official documents generally do not list the specific names or clinical trial numbers of the research studies.

---

Q: Is it common to have stomach upset from Funciobron B?

Regulatory documents classify gastrointestinal effects, such as nausea, vomiting, diarrhea, and pain in the upper stomach area, as uncommon adverse reactions. The term 'uncommon' means they are observed in less than 1 in 100 people but more than 1 in 1,000 people.

---

Q: Can Funciobron B cause a rash?

Official summaries state that skin rash and urticaria (hives) are classified as rare adverse reactions to the medicine. This means they are observed in less than 1 in 1,000 people but more than 1 in 10,000 people.

---

Q: Can I take Funciobron B with common vitamins like Vitamin D?

The official interaction profile details known interactions with specific drug classes. Regulatory sources do not document any clinically relevant unfavorable interactions specifically with common vitamins or mineral supplements.

---

Q: What is the chance of having a serious side effect from Funciobron B?

Serious adverse reactions, including severe allergic reactions (anaphylactic shock) and severe skin reactions, are formally documented in regulatory sources. The frequency of these serious events is classified as 'Not Known,' meaning the exact chance cannot be estimated from the currently available data.

---

Q: Will Funciobron B make me feel tired?

Adverse effects documented in some official regulatory summaries include dizziness (vertigo) and headache. Specific reports of fatigue or tiredness are not consistently listed for the single-active-ingredient formulation, though these effects may be accompanied by changes in concentration.

---

Q: How quickly is Funciobron B removed from the body?

Pharmacokinetic data available in regulatory sources describes how the medicine is processed by the body. The terminal elimination half-life, which indicates the time it takes for half of the drug to be eliminated, has been reported to be up to about 12 hours or between 13 and 40 hours, depending on the source.

---

Q: Is it safe to take Funciobron B if I have high blood pressure?

While there is no specific contraindication related solely to high blood pressure, the medicine is described in regulatory documents as a product requiring caution in patients who have pre-existing cardiovascular disorders or hypertension. This is a common consideration, especially in combination products that contain Funciobron B.

---

Q: Can I drink coffee while taking Funciobron B?

The official interaction profile lists specific drug classes that require caution. Regulatory sources do not document any clinically relevant unfavorable interactions specifically involving caffeine consumption or coffee.

---

Q: Can I take cold medicine while taking Funciobron B?

Official documents advise that co-administration is restricted with cough suppressants (antitussives). This restriction is in place to prevent respiratory secretions from accumulating due to the combined effect of the two medicines.

---

Q: Is it normal to feel a mild headache when first starting Funciobron B?

Headache is included in some regulatory summaries as a reported adverse effect of the medicine. This information is based on reports collected during clinical trials and post-marketing surveillance.

---

Q: Why do I need a prescription for Funciobron B?

The classification of the medicine varies internationally based on the local regulatory agency. It is classified as an over-the-counter (OTC) drug in many regions, while other jurisdictions classify it as a medicine that requires a prescription.

---

Q: What should I tell my dentist about Funciobron B?

Regulatory documents state that no specific drug interactions are documented that would affect common dental procedures or local anesthetics. It is generally advised to keep all healthcare providers informed of any medicines being used.

---

Q: Why is Funciobron B taken at a specific time of day?

The approved three-times-a-day (TID) dosing frequency is established based on the drug's half-life to ensure consistent therapeutic concentration in the body. Furthermore, some national labels suggest administering the medicine immediately after meals.

---

Q: Does Funciobron B affect blood sugar levels?

While Funciobron B itself is not primarily associated with this effect, some common combination products that include it alongside other agents (e.g., beta2-agonists) may carry a warning regarding the potential for effects on blood sugar levels.

---

Q: Can I drive or operate machinery while taking Funciobron B?

Regulatory documents advise caution and include warnings related to the potential impact on the ability to drive or operate machinery. This consideration is based on the documented occurrence of dizziness as a possible adverse effect.

---

Q: Can Funciobron B be used by people over 65?

There is no specific age-based restriction for people over 65 in official documents. The official documentation requires caution for all patients who have severe hepatic (liver) or renal (kidney) impairment.

Official Storage and Disposal Requirements

Regulatory documents specify strict conditions for the storage and disposal of Funciobron B to ensure its quality and stability.

Requirement Area	Official Labeling Statement
Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not refrigerate or freeze.
Protection	Keep the product in the original, tightly closed container. Protect from excessive moisture and light.
Stability (In-Use)	Discard any unused portion of the medicine 60 days after first opening the container.
Child Safety	Keep out of the sight and reach of children. The product should be dispensed in a child-resistant container.
Disposal	Dispose of unused or expired medication by returning it to an authorized drug take-back program. If a program is unavailable, mix the medicine with an unpalatable substance (such as kitty litter or used coffee grounds) and seal it in a container before placing it in household trash. Do not flush the medication down a toilet or pour it down a drain.

These mandated statements define how the product must be protected from environmental factors (heat, moisture, light) and outline the specific process that must be followed for the safe disposal of both unused and expired medicine.